[go: up one dir, main page]

AR122933A1 - Métodos para tratar la enfermedad cardiovascular - Google Patents

Métodos para tratar la enfermedad cardiovascular

Info

Publication number
AR122933A1
AR122933A1 ARP210101936A ARP210101936A AR122933A1 AR 122933 A1 AR122933 A1 AR 122933A1 AR P210101936 A ARP210101936 A AR P210101936A AR P210101936 A ARP210101936 A AR P210101936A AR 122933 A1 AR122933 A1 AR 122933A1
Authority
AR
Argentina
Prior art keywords
cardiovascular disease
methods
treat cardiovascular
disease
ziltivekimab
Prior art date
Application number
ARP210101936A
Other languages
English (en)
Inventor
Michael H Davidson
Rahul Kakkar
Madhav N Devalaraja
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR122933A1 publication Critical patent/AR122933A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La descripción proporciona métodos para tratar la enfermedad cardiovascular, incluidos pacientes con enfermedad cardiovascular aterosclerótica y/o enfermedad renal crónica. El método comprende la administración de una cantidad terapéuticamente eficaz de ziltivekimab.
ARP210101936A 2020-07-10 2021-07-08 Métodos para tratar la enfermedad cardiovascular AR122933A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063050441P 2020-07-10 2020-07-10

Publications (1)

Publication Number Publication Date
AR122933A1 true AR122933A1 (es) 2022-10-19

Family

ID=77126785

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101936A AR122933A1 (es) 2020-07-10 2021-07-08 Métodos para tratar la enfermedad cardiovascular

Country Status (5)

Country Link
US (1) US20230287105A1 (es)
EP (2) EP4309734A1 (es)
AR (1) AR122933A1 (es)
TW (1) TW202216763A (es)
WO (1) WO2022008702A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12026924B1 (en) * 2023-02-19 2024-07-02 Deep Render Ltd. Method and data processing system for lossy image or video encoding, transmission and decoding

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
SG172354A1 (en) 2009-01-29 2011-07-28 Medimmune Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JP6097702B2 (ja) 2011-03-03 2017-03-15 アペクシジェン， インコーポレイテッド 抗ｉｌ−６受容体抗体およびその使用方法
KR102709681B1 (ko) 2015-07-31 2024-09-26 메디뮨 리미티드 헵시딘 매개 장애의 치료 방법
CA3051865C (en) 2017-02-01 2023-01-17 Yale University Treatment of diuretic resistance
SG11202006157VA (en) * 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression

Also Published As

Publication number Publication date
TW202216763A (zh) 2022-05-01
WO2022008702A1 (en) 2022-01-13
US20230287105A1 (en) 2023-09-14
EP4309734A1 (en) 2024-01-24
EP4178673A1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
AR099707A1 (es) Composiciones y métodos para tratar trastornos renales
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
PA8849001A1 (es) Anticuerpos de c-met
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
PE20211065A1 (es) Metodo para tratar la epilepsia
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
PE20211196A1 (es) Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion
MX2022000143A (es) Metodos novedosos.
WO2018102687A3 (en) Combination therapy for treating cancer
AR119158A1 (es) Tratamientos de angioedema hereditario
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
PH12022552702A1 (en) Methods of treating diabetic kidney disease
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
AR119159A1 (es) Tratamientos de angioedema
AR122933A1 (es) Métodos para tratar la enfermedad cardiovascular
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
EA202193276A1 (ru) Способы лечения холангиокарциномы
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
DOP2017000069A (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
EA202091143A1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина
EA201291122A1 (ru) Средство для профилактики и лечения заболеваний, которые сопровождаются болью в органах мочеиспускания

Legal Events

Date Code Title Description
FB Suspension of granting procedure